Amylyx Pharmaceuticals, Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Amylyx Pharmaceuticals, Inc. (AMLX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$179.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$111.00K, a 156.35% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $197.00K.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$110.00K, a 246.67% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $75.00K.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $1.07M.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$438.00K, a 373.75% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $160.00K.
- Amylyx Pharmaceuticals, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$65.00K, a 600.00% decline from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$179.00K 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$111.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.07M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $956.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $805.00K 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $197.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$438.00K 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $87.00K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$149.00K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$110.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $160.00K 10-K · filed 2025-03-04 | |||
| 2023-09-30 | -$77.00K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $57.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $75.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$65.00K 10-K · filed 2024-02-22 | |||
| 2022-09-30 | -$572.00K 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$203.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$68.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $13.00K 10-K · filed 2024-02-22 | |||
| 2021-09-30 | $4.00K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $2.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |